8:00 AM ET
8-K
Capital Raise
Spyre Therapeutics Capital Raise of $350M
Spyre Therapeutics entered into an underwriting agreement for a public offering of 4,117,648 shares of common stock at $85.00 per share, expected to raise gross proceeds of approximately $350.0 million. The company intends to use the proceeds to advance its clinical programs in gastroenterology, rheumatology, and dermatology, including Phase 3 readiness and a new program for hidradenitis suppurativa.
- Value
- $350M
- Counterparty
- Jefferies LLC, TD Securities (USA) LLC, Leerink Partners LLC and Stifel, Nicolaus & Company, Incorporated